Published by
@ShahidNShah
@ShahidNShah
November 18, 2022
Online
Biomarker quantification plays an integral role in the drug development process, providing guidance for downstream decision-making that has shown to correlate positively with clinical trial success. Biomarker-based stratification enriches clinical populations, reducing cost and trial duration. However, the real value of biomarker insights have not been fully realized due the limitations in the development and implementation of effective biomarker strategies in many clinical programmes across therapeutic areas, resulting in the absence of predictive biomarkers in the latest drug approvals. It is also worth considering the prospect of applying machine-learning to biomarker assessment, which promises improved patient stratification of treatment response to drive drug development.
Continue reading at xtalks.com
Connecting innovation decision makers to authoritative information, institutions, people and insights.
Medigy accurately delivers healthcare and technology information, news and insight from around the world.
Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.
© 2024 Netspective Foundation, Inc. All Rights Reserved.
Built on Dec 20, 2024 at 12:59pm